AZELNIDIPINE INHIBITS MACROPHAGE ACTIVATION BY REDUCING THE EXPRESSION OF LOX–1 AND THE UPTAKE OF ACETYLATED LDL IN THP–1 CELLS  by Komoda, Hiroshi et al.
E2034
JACC March 12, 2013
Volume 61, Issue 10
Vascular Medicine 
azelnidipine inhiBiTs macrophage acTivaTion By reducing The expression of lox-1 and 
The upTake of aceTylaTed ldl in Thp-1 cells
Moderated Poster Contributions
Poster Sessions, Expo North
Saturday, March 09, 2013, 10:00 a.m.-10:45 a.m.
Session Title: Vascular Medicine Basic: Atherogenesis
Abstract Category: 33. Vascular Medicine: Basic
Presentation Number: 1125M-169
Authors: Hiroshi Komoda, Jun-ichi Oyama, Aya Shiraki, Koichi Node, Saga University, Saga, Japan
Background: Recently, it has been reported that some calcium-channel blockers (CCB) reduced atherosclerosis with anti-inflammatory or anti-
atherosclerotic effects in vivo. It is well known that monocytes or macrophages play important roles in atherosclerosis. However, the effects of CCB 
on macrophage activation remain unclear. The aim of the current study was to evaluate the effects of azelnidipine, a dihydropyridine L-type calcium 
channel, on the activation of macrophages and to elucidate precise mechanisms of CCB for atherosclerosis.
methods and results: THP-1 monocytes, human leukemic cell line, were stimulated with 10 ng/ml of phorbor myristate acetate (PMA) one 
hour after the pretreatment with 10 μM of azelnidipine or DMSO and harvested 48 or 72 hours after the intervention. Azelnidipine blocked the 
expression of adhesion molecule, intercellular Adhesion Molecule-1 (ICAM-1) by FACS analysis. ApoE and MMP9 which indicate as markers for 
macrophage differentiation were inhibited with azelnidipine evaluated by quantitative RT-PCR. The level of LOX-1 mRNA, a scavenger receptor, was 
also reduced significantly by pretreatment of 10 uM azelnidipine. Azelnidipine also lowered the uptake of DiI-ac-LDL (acetylated LDL). Although 
L-type calcium channel, Cav1.2, expressed 10-fold higher after PMA stimulation for 24 hours, knockdown of CACNA1C gene, which encodes Cav1.2 
protein in human, with siRNA could not inhibit macrophage activation. Therefore, these effects of azelnidipine on the macrophage differentiation 
were independent of CACNA1C gene.
conclusion: These results suggest that azelnidipine have the potent anti-atherosclerotic properties through the inhibition of macrophage 
activation.
